NCT00941486 is a Phase 2 clinical trial of FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis, sponsored by Shire.

Who is sponsoring NCT00941486?

NCT00941486 is sponsored by Shire.

What drugs are being tested in NCT00941486?

Interventions in NCT00941486: FST-100 Ophthalmic Suspension, Placebo.

What condition does NCT00941486 study?

NCT00941486 studies Acute Adenoviral Conjunctivitis.

Is NCT00941486 still recruiting?

NCT00941486 is currently terminated. Last updated 24 August 2021.

Last reviewed 2021-08-24 · How we verify

NCT00941486

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis

Terminated Phase 2 Last updated 24 August 2021

What this trial tests

Phase 2 trial testing FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis in 30 participants. Terminated before completion.

Timeline

30 June 2009

Primary endpoint
30 June 2010

30 June 2010

Quick facts

Lead sponsor	Shire
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	30 June 2009
Primary completion	30 June 2010
Estimated completion	30 June 2010
Sites	13 locations across United States

Drugs / interventions tested

FST-100 Ophthalmic Suspension — full drug profile →
Placebo

Conditions studied

Acute Adenoviral Conjunctivitis — all drugs for Acute Adenoviral Conjunctivitis →

Sponsor

Shire — full company profile →

Who can join

3 and older, any sex, with Acute Adenoviral Conjunctivitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the efficacy of FST-100 (PVP-I 0.4% and dexamethasone 0.1%) Ophthalmic Suspension in the treatment of suspected acute adenoviral conjunctivitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shire trials

Trials by the same sponsor.

NCT05067868 — A Study of Replagal in Children and Adults With Fabry Disease in India · Phase 4 · recruiting
NCT03878953 — A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism · Phase 3 · withdrawn
NCT04840667 — A Study of Replagal in Treatment-naïve Adults With Fabry Disease · Phase 3 · terminated
NCT04429984 — Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India · completed
NCT04440488 — ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study · Phase 4 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00941486 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shire
Last refreshed: 24 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00941486.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing